blocking factor

progression of tumor growth associated in vitro with blocking by serum of lymphocyte-mediated cytotoxicity; blocking factor appears to be soluble tumor antigen or antigen-antibody complex; has antigen-binding properties & is a glycoprotein

Networked: 156 relevant articles (4 outcomes, 17 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Szekeres-Bartho, Julia: 7 articles (01/2022 - 04/2005)
2.	Check, Jerome H: 7 articles (12/2021 - 08/2007)
3.	Adeola, Olayiwola: 5 articles (05/2022 - 01/2019)
4.	Check, Diane: 5 articles (12/2021 - 05/2014)
5.	Check, J H: 5 articles (01/2017 - 01/2005)
6.	Polgar, Beata: 4 articles (01/2016 - 08/2010)
7.	Madendag, Yusuf: 3 articles (08/2022 - 01/2018)
8.	Sahin, Erdem: 3 articles (08/2022 - 01/2018)
9.	Szekeres-Bartho, J: 3 articles (01/2020 - 06/2009)
10.	DeRouchey, Joel M: 3 articles (10/2019 - 11/2018)

Related Diseases

1.	Thrombosis (Thrombus) 01/01/2004 - "The clinical tolerability and the efficacy of low molecular weight heparins has established that inhibition of further thrombin generation, by blocking factor Xa alone can be an effective way of preventing thrombus growth without inactivating thrombin. " 01/01/2002 - "The clinical tolerability and the efficacy of low molecular weight heparins led to the concept that inhibition of further thrombin generation, by blocking factor Xa alone, can be an effective way of preventing thrombus growth without inactivating thrombin. "
2.	Leukemia 05/01/2014 - "Mifepristone causing complete remission of rapidly advancing leukemia with measurement of progesterone-induced blocking factor." 01/01/2018 - "It is shown in recent studies that progesterone-induced blocking factor is overexpressed in many malignant tumors such as breast, cervical, lymphoma, and leukemia. " 08/01/2007 - "Expression and modulation of progesterone induced blocking factor (PIBF) and innate immune factors in human leukemia cell lines by progesterone and mifepristone." 01/01/2007 - "Multiple human leukemia cell lines were evaluated for mRNA expression of an immunomodulatory protein called the progesterone-induced blocking factor (PIBF) that suppresses natural killer (NK) cell activity during normal pregnancy. "
3.	Lung Neoplasms (Lung Cancer) 12/01/1978 - "Immunocompetency was assessed before and after the operation in 40 patients with lung cancer by skin reaction against tuberculin (PPD) and dinitrochlorobenzene (DNCB), lymphocyte response to PHA, proportion of T-cells, macrophage migration inhibition test (MIT) and the presence of blocking factor. " 03/01/2023 - "The objective of this study is to provide a review of the large number of drugs and their efficacy as of 2022, for lung cancer, but also introduce a novel treatment that has the potential, based on one controlled murine lung cancer study and 5 anecdotal human cases, that showed marked palliative and longevity benefits in very advanced lung cancer with no other treatment options, i.e., progesterone receptor (PR) antagonists targeting the immunosuppressive protein, the progesterone induced blocking factor (PIBF). "
4.	Neoplasms (Cancer) 01/01/1979 - "This study has indicated that the cell mediated antitumor immune response of rats immunized with living tumor cells and the blocking factor in serum of rats with progressively growing tumors may be demonstrated by the LAI assay with incubation time prolonged to 20 hr (LAI assay-IT20). " 01/01/1976 - "In vitro studies demonstrated the evidence of sensitization of the patient against his own tumor, removal of blocking factor by the thoracic duct fistual from the circulation." 01/01/1990 - "Identification of TNF-LT blocking factor(s) in the serum and ultrafiltrates of human cancer patients." 01/01/1985 - "aureus indicate that specific blocking factor removal by plasma adsorption may not be the mechanism for causing tumor destruction. " 04/01/1984 - "It is our belief that failure to sufficiently concentrate the antibody in the tumor before operation was due to blocking factor in the serum of the patient. "
5.	Body Weight (Weight, Body) 03/01/2019 - "Initial body weight of pigs at the beginning of each digestibility trial was used as the blocking factor in a randomized complete block design. " 07/21/2023 - "A total of 120 day-old Ross 308 male broiler chicks were assigned to two dietary treatments using a randomized complete block design, with body weight as the blocking factor. " 04/10/2023 - "The experiment was designed as a randomized complete block design with body weight (BW) used as a blocking factor. " 01/03/2023 - "A total of 416 male broiler chickens with an initial body weight (BW) of 951 ± 111 g were allotted to five diets in a randomized complete block design with BW as a blocking factor on day 21 posthatching. " 12/08/2022 - "In experiment 1, rumen and blood parameters were evaluated using eight rumen-cannulated Nellore bulls with initial body weight (BW) of 763 ± 44 kg, distributed in a double Latin square 4 × 4. In experiment 2, 120 Nellore steers with initial BW of 380 ± 35 kg were used for performance evaluation, distributed in a randomized block design (blocking factor or initial BW). "

Related Drugs and Biologics

1.	Progesterone
2.	Thrombin
3.	Proteins (Proteins, Gene)
4.	Progesterone Receptors (Progesterone Receptor)
5.	Mifepristone (RU 486)
6.	Sodium Channels (Sodium Channel)
7.	Tablets
8.	spinosad
9.	Cytokines
10.	Antigens

Related Therapies and Procedures

1.	Therapeutics
2.	Immunotherapy
3.	Drug Therapy (Chemotherapy)
4.	Aftercare (After-Treatment)
5.	Self Care (Care, Self)